PFS Investments
ITCI icon

PFS Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PFS Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$221K Buy
+3,490
New +$217K ﹤0.01% 484

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PFS Investments's ITCI Position: Q2 2023 in Review

PFS Investments opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q2 2023: 3,490 shares worth $221K. The stake represents ﹤0.01% of the portfolio and ranks #484 among its holdings.

287 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • PFS Investments held 3,490 shares of Intra-Cellular Therapies Inc. worth $221K as of Q2 2023.
  • Intra-Cellular Therapies Inc. was a new PFS Investments position in Q2 2023.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of PFS Investments's portfolio in Q2 2023, its #484 holding.
  • 287 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.